Professional Documents
Culture Documents
Future Leaders in The Biotech Industry
Future Leaders in The Biotech Industry
Future Leaders in The Biotech Industry
number of shares market 52-week 52-week
company Symbol price currency
outstanding cap high low
Akebia Therapeutics Inc. -- -- -- -- -- --
Allos Therapeutics Inc. ALTH 8,41 104.724.779 880.735.375 8,79 5,34 USD
Amarin Corp. plc
AMRN 1,62 98.801.982 160.059.211 2,25 0,66 USD
ArQule Inc. ARQL 6,25 44.726.321 279.539.506 7,49 2,97 USD
Biota Holdings Ltd. ASX:BTA 2,29 178.950.022 409.795.544 3,47 0,63 AUD
Calistoga Pharmaceuticals Inc. -- -- -- -- -- --
Chelsea Therapeutics International Ltd. CHTP 3,7 40.200.406 148.741.504 7,51 1,47 USD
ChemoCentryx Inc. -- -- -- -- -- --
Chimerix Inc. -- -- -- -- -- --
Clinical Data Inc. CLDA 18,94 26.513.563 502.166.897 22,39 9,00 USD
Curis Inc. CRIS 3,11 75.559.319 234.989.474 3,70 1,11 USD
Cytori Therapeutics Inc. XMPA 3,18 0 0 6,20 0,97 EUR
Depomed Inc. DEPO 3,4 52.330.443 177.923.511 6,40 1,88 USD
Dyax Corp. DYAX 3,65 78.125.483 285.158.020 4,69 1,55 USD
Enobia Pharma Inc. -- -- -- -- -- --
Exact Sciences Corp. EXAS 4,75 35.832.021 170.202.100 5,25 0,97 USD
Five Prime Therapeutics Inc. -- -- -- -- -- --
Gemin X Pharmaceuticals Inc. -- -- -- -- -- --
GlobeImmune Inc. -- -- -- -- -- --
Inovio Biomedical Corp. INO 1,41 102.765.682 144.899.608 3,40 0,31 USD
iPierian Inc. -- -- -- -- -- --
KAI Pharmaceuticals Inc. -- -- -- -- -- --
KaloBios Pharmaceuticals Inc. -- -- -- -- -- --
Lux Biosciences Inc. -- -- -- -- -- --
Micromet Inc. MITI 7,84 69.212.460 542.625.697 8,98 2,83 USD
Neoprobe Corp. NEOP 1,75 81.890.508 143.308.389 2,30 0,35 USD
NeurogesX Inc. NGSX 9,48 17.725.959 168.008.409 10,57 2,01 USD
Newron Pharmaceuticals S.p.A. SIX: -- -- -- -- -- --
PDL BioPharma Inc. PDLI 6,43 119.674.377 769.506.224 9,32 6,05 USD
Pharming Group N.V. PHARM 0,39 154.501.037 59.637.401 0,40 0,38 EUR
Plexxikon Inc. -- -- -- -- -- --
Protalix Biotherapeutics Inc. PLX 6,52 80.745.296 526.459.328 12,50 2,13 USD
PTC Therapeutics Inc. -- -- -- -- -- --
Regulus Therapeutics Inc. -- -- -- -- -- --
Relypsa Inc. -- -- -- -- -- --
RXi Pharmaceuticals Corp. RXII 4,17 16.207.625 67.585.797 8,99 1,51 USD
Seaside Therapeutics LLC -- -- -- -- -- --
Singulex Inc. -- -- -- -- -- --
SuperGen Inc. SUPG 3,22 60.215.632 193.894.337 3,50 1,69 USD
Trubion Inc. TRBN 4,28 20.386.800 87.353.362 6,75 1,30 USD
Vivus Inc. VVUS 8,77 80.738.994 708.081.014 12,88 3,61 USD
Wilex AG, XETRA:WL6 -- -- -- -- -- --
Akebia Therapeutics Inc. – Akebia is developing an oral prolyl
hydroxylase inhibitor for anemia. The compound is in Phase Ib trials
with plans to move into Phase IIa trials mid‐year. In January, it
showed a dose‐responsive increase in levels of EPO vs. placebo in
Phase I trials without changing the levels of VEGF. The company
raised $15M in its series A financing in December 2008.
Calistoga Pharmaceuticals Inc. – Running Phase II/III trials of CAL‐101
in relapsed or refractory hematological malignancies. In December,
the oral small molecule inhibitor of phosphoinositide 3‐kinase (PI3K)
delta produced 6 partial responses in 7 patients with mantle cell
lymphoma and 4 partial responses in 17 patients with chronic
lymphocytic leukemia. The company raised $30M in its series B
round last May.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) –
Anticipating Phase III data in 3Q10 for droxidopa in neurogenic
orthostatic hypotension (NOH). The oral synthetic precursor of
norepinephrine has Fast Track and Orphan Drug designations to treat
symptomatic NOH in the U.S. and Orphan designation to treat
orthostatic hypotension in Europe. The company raised $18M in a
direct public offering in February.
Chimerix Inc. – Chimerix is developing new chemical entities for life‐
threatening viral diseases, including adenovirus, CMV, smallpox, HIV,
HCV and influenza. CMX001, an orally available chemical
modification of cidofovir, is in Phase II trials to treat dsDNA viral
infections, including CMV and BK viruria in immunocompromised
patients and transplant recipients. A second clinical‐stage NCE,
CMX157, is in development for HIV. The company raised $16M in its
series E financing last August.
Clinical Data Inc. (NASDAQ:CLDA) – Submitted in March an NDA for
vilazodone, a mixed selective serotonin reuptake inhibitor and partial
serotonin receptor agonist, to treat major depressive disorder. The
company’s PGxHealth division markets a number of
pharmacogenomic and predictive diagnostic tests. The company has
raised more than $120M since 2008.
Curis Inc. (NASDAQ:CRIS) – Running Phase II trials of GDC‐0449 in
colorectal cancer, basal cell carcinoma and ovarian cancer. The small
molecule antagonist of the Hedgehog pathway is partnered with
Genentech Inc., a unit of Roche (SIX:ROG; OTCQX:RHHBY). CUDC‐101,
a small molecule inhibitor of epidermal growth factor receptor 2,
EGFR and histone deacetylase, is in Phase I testing for solid tumors.
The company raised $16M in a January financing.
Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA) – Anticipating
a 1H10 launch of its PureGraft device that facilitates autologous
adipose tissue transfer for aesthetic body contouring. The company
has raised more than $50M since 2008.
Depomed Inc. (NASDAQ:DEPO) – The company develops improved
formulations of products using its AcuForm polymer‐based
technology. Its marketed products include Glumetza metformin for
diabetes and Proquin XR for bacterial infection and urinary tract
infections. Anticipates submitting an NDA shortly for DM‐1796, an
extended‐release gabapentin to treat post‐herpetic neuralgia. Serada
gabapentin GR is in Phase III trials for menopausal hot flashes.
Dyax Corp. (NASDAQ:DYAX) – Coming off December’s FDA approval
of Kalbitor ecallantide to treat acute attacks of hereditary
angioedema (HAE) in patients 16 years and up. Kalbitor is a
subcutaneously delivered yeast‐derived recombinant plasma
kallikrein inhibitor. The company raised more than $100M in 2009.
Enobia Pharma Inc. – Coming off positive Phase I/II data in
September for ENB‐0400 to treat hypophosphatasia in infants. The
compound, a fusion protein incorporating the catalytic domain of
human tissue non‐specific alkaline phosphatase and a bone‐targeting
peptide is in an open‐label Phase II trial with data expected in 2H10.
ENB‐0040 has Fast Track designation in the U.S. and Orphan Drug
designation for the indication in the U.S. and EU. The company raised
$50M in its series C financing last August.
Five Prime Therapeutics Inc. – Five Prime is developing protein and
antibody therapeutics for oncology, metabolic disease and
immunology using its cell‐based and in vivo screening systems. In
March, Five Prime received an undisclosed milestone payment from
Johnson & Johnson (NYSE:JNJ) subsidiary Centocor triggered by the
selection of a therapeutic compound for immunology related
indications. The company has raised $135M in three venture rounds.
GlobeImmune Inc. – GlobeImmune is developing targeted molecular
immunogens – called Tarmogens – which are recombinant yeast cells
that express antigens that stimulate an immune response. The
company has two Tarmogens in Phase II testing: GI‐4000 for
pancreatic and non‐small cell lung cancers; and GI‐5005 for chronic
HCV. The company raised $17.5M in its series E financing in January.
I/II trials of ChronVac‐C to treat HCV. The company raised $30M last
July.
iPierian Inc. – iPierian is using its induced pluripotent stem cell (iPS)
technology to identify new molecular targets and develop drugs for
neurological disorders, including Parkinson’s disease, spinal muscular
atrophy and amyotrophic lateral sclerosis. The company raised
$31.5M in its series A financing last year.
Squibb Co. (NYSE:BMY) are running Phase IIb trials of KAI‐9803, a PKC
delta inhibitor, to reduce myocardial injury. Raised more than $60M
in two private rounds.
Lux Biosciences Inc. – MAA under review in Europe for Luveniq
voclosporin to treat non‐infectious uveitis involving the intermediate
or posterior segments of the eye. In February, Lux submitted an NDA
to FDA and requested Priority Review. The oral formulation of a
cyclosporine analog that inhibits calcineurin has Orphan Drug
designation in Europe. The company raised $50M in its series B
financing last October.
Micromet Inc. (NASDAQ:MITI) – Micromet is developing Biospecific
T cell engager (BiTE) antibodies for solid tumors and hematologic
disorders. In December, Bayer AG exercised its option to receive
exclusive, worldwide rights to a BiTE antibody against an undisclosed
target in a deal that could bring more than $400M to Micromet, plus
double‐digit royalties. The company has raised more than $150M in a
pair of follow‐on offerings since last July, including a $70M deal in
March.
pain in non‐diabetic adults. The company raised $25M in a December
2007 financing.
The company raised $11M in a January financing.
Plexxikon Inc. – The company is developing small molecules to treat
a range of diseases including cancer, rheumatoid arthritis, pain and
diabetes. Partner Roche (SIX:ROG; OTCQX:RHHBY) began in January a
Phase III trial of PLX4032 to treat metastatic melanoma in patients
with the V600 mutation in the BRAF gene. Expecting interim Phase III
data in the fourth quarter. The company has raised more than $65M
in private rounds.
PTC Therapeutics Inc. – Running Phase III trials of Ataluren to treat
nonsense‐mutation‐mediated cystic fibrosis and nonsense‐mutation
hemophilia A and hemophilia B. The small molecule facilitates the
complete translation of proteins containing nonsense mutations. The
company raised $50M in a private financing last December.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) – RXi is developing RNAi‐
based therapeutics for a range of disorders. The company has
preclinical programs in liver and inflammatory diseases. The
company raised $16M this March.
September.
Singulex Inc. – Singulex is developing the Erenna Immunoassay
System, which combines single molecule detection technology with
clinical assays for quantitatively detecting biomarkers at sub‐
picogram concentrations. The company, which plans to launch the
service into the CLIA market shortly, raised $19M in its series E
financing in 2009.
lymphocytic leukemia by year end. Its partners include Facet Biotech
Corp. (NASDAQ:FACT) and Pfizer Inc. (NYSE:PFE).
Vivus Inc. (NASDAQ:VVUS) – NDA under review at FDA for Qnexa
phentermine/topiramate to treat obesity. The PDUFA date is Oct. 28.
The company raised more than $100M in a September follow‐on.